111 Capital’s Biogen BIIB Stock Holding History

111 Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,130	Closed	-$298K	–	352
2025 Q3	$298K	Sell	2,130 -2,137	-50%	-$289K	0.06%	321
2025 Q2	$536K	Sell	4,267 -1,353	-24%	-$169K	0.09%	239
2025 Q1	$769K	Buy	+5,620	New	+$803K	0.15%	157

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

111 Capital's BIIB Position: Q4 2025 in Review

111 Capital sold out of Biogen (BIIB) in Q4 2025, closing a stake of 2,130 shares — an estimated $298K sold.

111 Capital first reported a position in BIIB in Q1 2025 and held it in 3 quarters. The position peaked at $769K in Q1 2025. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

111 Capital reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
111 Capital sold 2,130 Biogen shares in Q4 2025, an estimated $298K.
111 Capital first reported a position in Biogen in Q1 2025 and held it in 3 quarters.
111 Capital's Biogen position peaked at $769K in Q1 2025.
1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on 111 Capital's 13F filing for Q4 2025, filed 11 Feb 2026.